Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

Attorney Docket No.	21500		
First Inventor	Banner et al		
Title	Novel Mandelic Acid D		
Everess Mail Lahel No.	EL 912161353 US		

(Only for new nonprovisional applications under 37 CFR 1.53(b))

			Mall Stop Patent Applic				
	CATION ELEMENTS	ADDRESS TO:	Commissioner for Pater P.O. Box 1450	nts FO			
See MPEP chapter 600 c	concerning utility patent application contents.		Alexandria VA 22313-1	450			
2. Applicant claims s See 37 CFR 1.27. 3. Specification (preferred arrangem - Descriptive title of - Cross Reference to - Statement Regardi - Reference to sequence or a computer prog - Background of the - Brief Summary of to	[Total Pages 225] Jent set forth below) the invention o Related Applications ing Fed sponsored R & D ence listing, a table, gram listing appendix Invention the Invention on	8. Nucleotide and/or A (if applicable, all nec a. Computer b. Specifica i. CD-ii. Pap c. Statemer	cessary) r Reader Form (CRF) tion Sequence Listing of	Submission 2421 above copies			
	S.C. 113) [Total Sheets]		Papers (cover sheet & (h) Statement	document(s)) 1 Power of			
5. Oath or Declaration [Total Sheets 3] a. Newly executed (original or copy)		10.					
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)							
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76		(Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other:					
	PLICATION, check appropriate box, and supplies the state of the state		n below and in the first	sentence of the			
Specification following the title, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No.: Art Unit:							
For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.							
The Incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS							
Customer Number: 00151 OR Correspondence address below							
Name							
Address							
City		State	Zip Cod	le l			
Country	Te	lephone	Fax				
Name (Print/Type) Bernard Lau							
Signature	10 Mil	MM	Date	Nov. 21, 2003			

This collection of information is required by 37 GFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality'ls governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110 Case Docket <u>21500</u> November 21, 2003

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the patent application of

Banner et al

For: NOVEL MANDELIC ACID DERIVATIVES

1. The fee has been calculated as shown below:

CLAIMS					
FOR	NO. FILED	NO. EXTRA	RATE	FEE	
TOTAL CLAIMS	67 - 20	47	x \$18	846	
INDEP. CLAIMS	- 3	0	x \$86		
MULTIPLE DI	EPENDENT CLAI	MS PRESENTED	+ \$290	290	
		BASIC FEE		\$770	
TOTAL <u>\$ 1906</u>					

Please charge Deposit Account No. 08-2525 in the amount noted above.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525, including those under 37 C.F.R. § 1.16 and 1.17. This sheet is provided in duplicate.

Continue to address all communications to:

George W. Johnston Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110

NO. 08-2525

OUR ORDER NO. <u>519</u>5

Attorney for Applicant(s)

Bernard Lau (Reg. No. 38218)

136625

Certification under 37 CFR 1.10

I hereby certify that this form and all documents cited on this form are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number:

EL 912161353 US

addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on November 21, 2003

Date

Marta Swaryczewsky

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Papers Submitted for Case Docket 21500: Patent Application Transmittal Form, Application Data Sheet, Fee Transmittal Form, Specification, Declaration, Information Disclosure Statement